Global Blood Therapeutics, Inc.
Histone methyltransferase inhibitors
Last updated:
Abstract:
The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Also provided are pharmaceutical compositions containing such compounds as well as processes and intermediates for preparing such compounds.
Status:
Grant
Type:
Utility
Filling date:
15 Feb 2017
Issue date:
22 Feb 2022